There are 2789 resources available
1338P - A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC
Presenter: Natalia Fadeeva
Session: ePoster Display
1296P - Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Presenter: Alberto Bongiovanni
Session: ePoster Display
1298P - PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
Presenter: Sally Lau
Session: ePoster Display
1299P - Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Presenter: Konstantinos Rounis
Session: ePoster Display
1248P - Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?
Presenter: Hasan Kobat
Session: ePoster Display
1301P - Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
Presenter: Ari VanderWalde
Session: ePoster Display
1367TiP - IMPRINTER: An open label, multi-center, dose escalation/expansion, phase I study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Presenter: Rita Laeufle
Session: ePoster Display
1300P - A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Presenter: lin wu
Session: ePoster Display
1840P - Impact of age, comorbidities and polypharmacy on survival in advanced cancers
Presenter: David Dawe
Session: ePoster Display